http://money.msn.com/business-news/article.aspx?feed=AP&date=20120612&id=15214497
June 12, 2012 1:05 PM ET
"Although the company believes its new products will enable the company's top-line to grow in the second half of calendar year 2012, it remains to be seen, as it is very difficult for new products to show traction during downturns," Kang wrote in a note to investors.
The analyst backed his "Buy" rating citing Finisar's current valuation, but cut his price target to $18.70 from $27.20, saying that the company's profits for fiscal 2013 and fiscal 2014 will be lower than he previously expected.
NAME LAST CHNG % CHNG
FNSR 13.31 -0.62 -4.45
Kirk out
#board-1574
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM